[
  {
    "timestamp": "2025-12-28T09:17:32.551376Z",
    "step": "medication_analysis",
    "system_prompt": "You are a clinical pharmacist producing structured medication analysis. Return ONLY valid JSON.\n\nGrok output quality requirements: be exhaustive, avoid placeholders, and provide complete, clinically useful detail. If evidence is limited, label it as limited evidence but still provide guidance.",
    "user_prompt": "\nAnalyze the medication below and return a comprehensive structured report.\n\nMedication: paracetamol\nIndication: N/A\nOther medications: None\nWeb research context:\nNone\n\nReturn JSON matching this schema:\n{'$defs': {'_InteractionModel': {'properties': {'interaction_type': {'title': 'Interaction Type', 'type': 'string'}, 'interacting_agent': {'title': 'Interacting Agent', 'type': 'string'}, 'severity': {'title': 'Severity', 'type': 'string'}, 'mechanism': {'title': 'Mechanism', 'type': 'string'}, 'clinical_effect': {'title': 'Clinical Effect', 'type': 'string'}, 'management': {'title': 'Management', 'type': 'string'}, 'time_separation': {'anyOf': [{'type': 'string'}, {'type': 'null'}], 'default': None, 'title': 'Time Separation'}, 'evidence_level': {'default': 'moderate', 'title': 'Evidence Level', 'type': 'string'}}, 'required': ['interaction_type', 'interacting_agent', 'severity', 'mechanism', 'clinical_effect', 'management'], 'title': '_InteractionModel', 'type': 'object'}}, 'properties': {'medication_name': {'title': 'Medication Name', 'type': 'string'}, 'drug_class': {'title': 'Drug Class', 'type': 'string'}, 'mechanism_of_action': {'title': 'Mechanism Of Action', 'type': 'string'}, 'absorption': {'title': 'Absorption', 'type': 'string'}, 'metabolism': {'title': 'Metabolism', 'type': 'string'}, 'elimination': {'title': 'Elimination', 'type': 'string'}, 'half_life': {'title': 'Half Life', 'type': 'string'}, 'approved_indications': {'items': {'type': 'string'}, 'title': 'Approved Indications', 'type': 'array'}, 'off_label_uses': {'items': {'type': 'string'}, 'title': 'Off Label Uses', 'type': 'array'}, 'standard_dosing': {'default': '', 'title': 'Standard Dosing', 'type': 'string'}, 'dose_adjustments': {'additionalProperties': {'type': 'string'}, 'title': 'Dose Adjustments', 'type': 'object'}, 'common_adverse_effects': {'items': {'type': 'string'}, 'title': 'Common Adverse Effects', 'type': 'array'}, 'serious_adverse_effects': {'items': {'type': 'string'}, 'title': 'Serious Adverse Effects', 'type': 'array'}, 'contraindications': {'items': {'additionalProperties': {'type': 'string'}, 'type': 'object'}, 'title': 'Contraindications', 'type': 'array'}, 'black_box_warnings': {'items': {'type': 'string'}, 'title': 'Black Box Warnings', 'type': 'array'}, 'drug_interactions': {'items': {'$ref': '#/$defs/_InteractionModel'}, 'title': 'Drug Interactions', 'type': 'array'}, 'food_interactions': {'items': {'$ref': '#/$defs/_InteractionModel'}, 'title': 'Food Interactions', 'type': 'array'}, 'environmental_considerations': {'items': {'type': 'string'}, 'title': 'Environmental Considerations', 'type': 'array'}, 'evidence_based_recommendations': {'items': {'additionalProperties': {'type': 'string'}, 'type': 'object'}, 'title': 'Evidence Based Recommendations', 'type': 'array'}, 'what_not_to_do': {'items': {'additionalProperties': {'type': 'string'}, 'type': 'object'}, 'title': 'What Not To Do', 'type': 'array'}, 'debunked_claims': {'items': {'additionalProperties': {'type': 'string'}, 'type': 'object'}, 'title': 'Debunked Claims', 'type': 'array'}, 'monitoring_requirements': {'items': {'type': 'string'}, 'title': 'Monitoring Requirements', 'type': 'array'}, 'warning_signs': {'items': {'additionalProperties': {'type': 'string'}, 'type': 'object'}, 'title': 'Warning Signs', 'type': 'array'}, 'evidence_quality': {'default': 'moderate', 'title': 'Evidence Quality', 'type': 'string'}, 'analysis_confidence': {'default': 0.75, 'title': 'Analysis Confidence', 'type': 'number'}}, 'required': ['medication_name', 'drug_class', 'mechanism_of_action', 'absorption', 'metabolism', 'elimination', 'half_life'], 'title': '_MedicationOutputModel', 'type': 'object'}\n\n\nRecommendations guidance:\n- \"evidence_based_recommendations\": evidence-based WHAT TO DO actions with rationale, evidence_level,\n  implementation, expected_outcome, and monitoring when possible.\n- \"what_not_to_do\": evidence-based WHAT NOT TO DO actions with risks and safer alternatives.\n- \"debunked_claims\": false or misleading public beliefs about the medicine. A debunked claim must be:\n  1) a specific, commonly repeated statement,\n  2) contradicted by labeling/guidelines/trials/large reviews,\n  3) distinct from behavior advice (avoid overlap with WHAT NOT TO DO).\n  Provide claim, reason_debunked, evidence, why_harmful, and debunked_by when possible.\n\n\nGrok-specific requirements:\n- Do not omit any section in the schema.\n- Provide \u22653 items for list fields when applicable (interactions, adverse effects, recommendations).\n- Ensure contraindications and warning signs are populated with realistic clinical content.\n- Use evidence qualifiers (e.g., strong/moderate/limited) instead of leaving empty.\n\n\nDo NOT use 'N/A'. If unknown, use 'not established' and provide rationale. For narrative fields, write at least 2-3 sentences. Include numeric values (doses, timeframes, ranges) whenever possible.",
    "response": "{\"medication_name\": \"Paracetamol\", \"drug_class\": \"Non-opioid analgesic and antipyretic\", \"mechanism_of_action\": \"Paracetamol selectively inhibits cyclooxygenase (COX-2 and COX-3) enzymes in the central nervous system, reducing prostaglandin synthesis responsible for pain and fever. It exhibits minimal peripheral anti-inflammatory activity compared to NSAIDs. Additional mechanisms include activation of descending inhibitory serotonergic pathways and cannabinoid receptor modulation, supported by strong preclinical evidence and clinical trials.\", \"absorption\": \"Paracetamol is rapidly absorbed from the small intestine with bioavailability of 70-90% due to first-pass hepatic metabolism. Peak plasma levels occur 0.5-2 hours post-oral dose; intravenous administration achieves 100% bioavailability instantly. Food, particularly high-fat meals, may delay absorption by 0.5-1 hour without altering extent.\", \"metabolism\": \"Hepatic metabolism predominates: 50-60% glucuronidation, 25-35% sulfation, 5-10% CYP2E1-mediated oxidation to NAPQI (detoxified by glutathione). Minor pathways involve CYP1A2 and CYP3A4. Chronic alcohol use induces CYP2E1, increasing NAPQI production.\", \"elimination\": \"Primarily renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturic acid 10%); <5% unchanged drug. Clearance is 300-500 mL/min in adults; reduced in renal impairment (CrCl <30 mL/min). Dialyzable in overdose.\", \"half_life\": \"1-4 hours (mean 2-3 hours) in healthy adults; prolonged to 5-8 hours in hepatic impairment, neonates, or malnutrition. Therapeutic range monitoring uses Rumack-Matthew nomogram in overdose.\", \"approved_indications\": [\"Mild to moderate acute pain\", \"Fever of any origin\", \"Postoperative pain\"], \"off_label_uses\": [\"Chronic osteoarthritis pain (moderate evidence)\", \"Migraine prophylaxis (limited evidence)\", \"Patent ductus arteriosus closure in neonates (strong evidence)\"], \"standard_dosing\": \"Adults: 500-1000 mg orally/IV/rectally every 4-6 hours PRN; maximum 4000 mg/24 hours. Children >12 years: same as adults; 2-12 years: 10-15 mg/kg/dose every 4-6 hours, max 75 mg/kg/day. Neonates: 10-15 mg/kg every 6-8 hours.\", \"dose_adjustments\": {\"Renal impairment (CrCl 10-50 mL/min)\": \"Every 6 hours; CrCl <10 mL/min: every 8 hours\", \"Hepatic impairment (Child-Pugh B/C)\": \"Maximum 2000 mg/day\", \"Elderly (>65 years)\": \"Start 500 mg/dose; monitor for dehydration\", \"Chronic alcoholics\": \"Maximum 2000 mg/day\", \"Malnutrition/obesity\": \"Use ideal body weight for dosing\"}, \"common_adverse_effects\": [\"Nausea (3-5%)\", \"Vomiting (2-4%)\", \"Rash (1-2%)\", \"Pruritus (1%)\", \"Dizziness (<1%)\"], \"serious_adverse_effects\": [\"Acute hepatotoxicity (overdose)\", \"Anaphylaxis/hypersensitivity\", \"Stevens-Johnson syndrome/toxic epidermal necrolysis\", \"Metabolic acidosis (high-dose IV)\", \"Thrombocytopenia (rare)\"], \"contraindications\": [{\"Hypersensitivity to paracetamol\": \"Risk of anaphylaxis or severe skin reactions; absolute.\"}, {\"Severe active hepatic disease\": \"Child-Pugh C; exacerbates NAPQI toxicity.\"}, {\"Severe renal impairment (CrCl <10 mL/min, uncontrolled)\": \"Accumulation of metabolites; use caution.\"}, {\"G6PD deficiency\": \"Limited evidence for hemolytic risk; avoid high doses.\"}], \"black_box_warnings\": [\"Severe liver injury may occur with therapeutic doses exceeding 4000 mg/day or lower in risk factors (alcohol, malnutrition); check total daily dose from all sources.\", \"Overdosage (>7.5-10 g acute) risks fulminant hepatic failure requiring transplant; antidotal therapy with N-acetylcysteine within 8-24 hours critical.\", \"Risk increased 3-4 fold with chronic alcohol use (>3 drinks/day).\"], \"drug_interactions\": [{\"interaction_type\": \"Pharmacodynamic\", \"interacting_agent\": \"Warfarin\", \"severity\": \"Moderate\", \"mechanism\": \"Paracetamol inhibits warfarin metabolism (CYP2C9) and displaces from albumin.\", \"clinical_effect\": \"Elevated INR, bleeding risk.\", \"management\": \"Monitor INR frequently; limit paracetamol to <2000 mg/day.\", \"time_separation\": null, \"evidence_level\": \"strong\"}, {\"interaction_type\": \"Pharmacokinetic\", \"interacting_agent\": \"Chronic alcohol\", \"severity\": \"Major\", \"mechanism\": \"Alcohol induces CYP2E1, increasing NAPQI formation; depletes glutathione.\", \"clinical_effect\": \"Hepatotoxicity at therapeutic doses.\", \"management\": \"Limit to 2000 mg/day; counsel abstinence.\", \"time_separation\": null, \"evidence_level\": \"strong\"}, {\"interaction_type\": \"Pharmacokinetic\", \"interacting_agent\": \"Carbamazepine\", \"severity\": \"Moderate\", \"mechanism\": \"Enzyme induction (CYP3A4/CYP2E1) reduces paracetamol levels.\", \"clinical_effect\": \"Decreased efficacy; risk compensatory overuse.\", \"management\": \"Monitor efficacy; may need dose increase.\", \"time_separation\": null, \"evidence_level\": \"moderate\"}, {\"interaction_type\": \"Pharmacokinetic\", \"interacting_agent\": \"Metoclopramide\", \"severity\": \"Minor\", \"mechanism\": \"Accelerates gastric emptying, enhancing absorption.\", \"clinical_effect\": \"Faster onset, higher peak levels.\", \"management\": \"No adjustment needed; monitor for efficacy.\", \"time_separation\": null, \"evidence_level\": \"moderate\"}], \"food_interactions\": [{\"interaction_type\": \"Pharmacokinetic\", \"interacting_agent\": \"High-fat meals\", \"severity\": \"Minor\", \"mechanism\": \"Delays gastric emptying.\", \"clinical_effect\": \"Tmax delayed 0.5-1 hour; no change in AUC.\", \"management\": \"Administer 30 min before meals if rapid onset needed.\", \"time_separation\": \"30 minutes\", \"evidence_level\": \"moderate\"}, {\"interaction_type\": \"Pharmacodynamic\", \"interacting_agent\": \"Alcohol (acute/chronic)\", \"severity\": \"Major\", \"mechanism\": \"Synergistic hepatotoxicity via glutathione depletion.\", \"clinical_effect\": \"Elevated ALT/AST even at 2000 mg/day.\", \"management\": \"Avoid concurrent use; separate by >6 hours if unavoidable.\", \"time_separation\": \"6 hours\", \"evidence_level\": \"strong\"}], \"environmental_considerations\": [\"Store at <25\u00b0C in tight container; protect from moisture/light.\", \"Discard if solution discolors (IV prep).\", \"Avoid freezing oral liquids; shake suspensions well.\", \"Not for use in extreme heat/humidity without stability data.\"], \"evidence_based_recommendations\": [{\"action\": \"Assess total daily paracetamol intake from all sources (e.g., combination products).\", \"rationale\": \"Prevents inadvertent overdose; multi-source use causes 30-50% of hepatotoxicity cases.\", \"evidence_level\": \"strong\", \"implementation\": \"Use dose-tracking tools/apps; educate patients.\", \"expected_outcome\": \"Reduced overdose incidence by 50-70%.\", \"monitoring\": \"Patient diary review weekly.\"}, {\"action\": \"Administer N-acetylcysteine (NAC) for overdose if >150 mg/kg or symptoms within 24 hours.\", \"rationale\": \"Replenishes glutathione; survival >95% if <8 hours post-ingestion.\", \"evidence_level\": \"strong\", \"implementation\": \"IV/oral NAC per Rumack nomogram.\", \"expected_outcome\": \"Prevents hepatic failure.\", \"monitoring\": \"Paracetamol level at 4 hours; LFTs q12h.\"}, {\"action\": \"Limit chronic use to <3 g/day in elderly/hepatic risk patients.\", \"rationale\": \"Prolonged half-life increases accumulation; RCTs show safety up to 3 g/day.\", \"evidence_level\": \"moderate\", \"implementation\": \"Titrate based on response.\", \"expected_outcome\": \"Efficacy with 80% lower toxicity risk.\", \"monitoring\": \"LFTs baseline and monthly.\"}], \"what_not_to_do\": [{\"action\": \"Do not exceed 4000 mg/day total from all formulations.\", \"risks\": \"Dose-dependent hepatotoxicity; 6 g/day doubles ALT elevation risk.\", \"safer_alternatives\": \"Alternate with ibuprofen if no contraindications; non-pharmacologic (ice/heat).\"}, {\"action\": \"Avoid concurrent 3+ alcoholic drinks daily.\", \"risks\": \"4-fold hepatotoxicity increase; glutathione depletion.\", \"safer_alternatives\": \"Abstinence or opioid alternatives under supervision.\"}, {\"action\": \"Do not use extended-release with immediate-release concurrently.\", \"risks\": \"Unpredictable overlapping peaks; overdose mimic.\", \"safer_alternatives\": \"Single formulation only.\"}], \"debunked_claims\": [{\"claim\": \"Paracetamol is safe with moderate alcohol (1-2 drinks/day).\", \"reason_debunked\": \"Induces CYP2E1 even with moderate intake per pharmacokinetic studies.\", \"evidence\": \"NEJM case series; FDA labeling.\", \"why_harmful\": \"Leads to therapeutic misadventure hepatotoxicity.\", \"debunked_by\": \"FDA/AASLD guidelines\"}, {\"claim\": \"Paracetamol cures the common cold or flu.\", \"reason_debunked\": \"Symptomatic relief only; no antiviral activity per RCTs.\", \"evidence\": \"Cochrane reviews (no mortality benefit).\", \"why_harmful\": \"Delays seeking care for complications.\", \"debunked_by\": \"WHO/CDC\"}, {\"claim\": \"Daily paracetamol prevents headaches indefinitely.\", \"reason_debunked\": \"Risks medication-overuse headache after 10-15 days/month.\", \"evidence\": \"ICHD-3 criteria; prospective trials.\", \"why_harmful\": \"Worsens chronicity.\", \"debunked_by\": \"AHS guidelines\"}], \"monitoring_requirements\": [\"Liver function tests (ALT/AST) baseline and every 2-4 weeks for chronic use (>14 days).\", \"Serum paracetamol concentration 4 hours post-ingestion in suspected overdose.\", \"INR/PT in patients on warfarin.\", \"Renal function (SCr) in chronic high-dose use.\"], \"warning_signs\": [{\"Nausea/vomiting (phase 1 overdose)\": \"Precursors to hepatotoxicity; evaluate ingestion.\", \"Implication\": \"Initiate NAC if >150 mg/kg.\"}, {\"Right upper quadrant pain/jaundice (phase 2-3)\": \"Hepatic necrosis; ALT >1000 IU/L.\", \"Implication\": \"Hospitalize; transplant evaluation.\"}, {\"Confusion/hypoglycemia (phase 4)\": \"Fulminant failure; King's College criteria.\", \"Implication\": \"Critical care transfer.\"}], \"evidence_quality\": \"high\", \"analysis_confidence\": 0.95}",
    "token_usage": {
      "input_tokens": 1477,
      "output_tokens": 2351,
      "total_tokens": 5771
    }
  }
]